Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer

[1]  P. Forget,et al.  A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research , 2017, Front. Oncol..

[2]  Bruno Manadas,et al.  SWATH‐MS as a tool for biomarker discovery: From basic research to clinical applications , 2017, Proteomics.

[3]  Hendrik Koffijberg,et al.  Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility , 2017, International journal of molecular sciences.

[4]  John F. Timms,et al.  Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset , 2015, BioMed research international.

[5]  Ruedi Aebersold,et al.  Quantitative variability of 342 plasma proteins in a human twin population , 2015 .

[6]  Ulf Gyllensten,et al.  Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs , 2014, Nature Communications.

[7]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[8]  H. Langen,et al.  Antibody‐based proteomics and biomarker research—Current status and limitations , 2014, Proteomics.

[9]  S. Pitteri,et al.  Performance evaluation of affinity ligands for depletion of abundant plasma proteins. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  Olga Vitek,et al.  A statistical model-building perspective to identification of MS/MS spectra with PeptideProphet , 2012, BMC Bioinformatics.

[11]  J. Pennings,et al.  A Bead-Based Multiplexed Immunoassay to Evaluate Breast Cancer Biomarkers for Early Detection in Pre-Diagnostic Serum , 2012, International journal of molecular sciences.

[12]  S. Hanash,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[13]  Diederick E Grobbee,et al.  Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study , 2011, BMC Cancer.

[14]  R. Aebersold,et al.  A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.

[15]  Jacob Kennedy,et al.  Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. , 2010, Cancer research.

[16]  S. Hanash,et al.  Confounding Effects of Hormone Replacement Therapy in Protein Biomarker Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[17]  Gary Goodman,et al.  Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study , 2010, Journal of the National Cancer Institute.

[18]  J. Manson,et al.  Postmenopausal estrogen and progestin effects on the serum proteome , 2009, Genome Medicine.

[19]  David C Muddiman,et al.  Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality. , 2009, Annual review of analytical chemistry.

[20]  Jacob J. Kennedy,et al.  Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings , 2009, Genome Medicine.

[21]  Veronika A. Glukhova,et al.  Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. , 2006, Journal of proteome research.

[22]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.